1. Similar long‐term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV‐1‐infected patients in a retrospective, real‐life cohort of 14 years. Issue 9 (3rd July 2018) Authors: Krznaric, I; Bickel, M; Carganico, A; De Leuw, P; Haberl, A; Knecht, G; Koegl, C; Lauscher, P; Schüttfort, G; Stephan, C; Wolf, E; Wolf, T Journal: HIV medicine Issue: Volume 19:Issue 9(2018) Page Start: 662 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗